Article History
Received: 23 February 2017
Revised: 14 April 2017
Accepted: 19 April 2017
First Online: 26 May 2017
Competing interests
: GRS serves as President and Chief Scientific Officer and has equity in Nano3D Biosciences. WA and RP are founders of AAVP BioSystems, which has licensed intellectual property related to the adeno-associated virus/phage (AAVP) technology, and they are inventors on patent applications and entitled to standard royalties if commercialization occurs. The University of New Mexico Health Sciences Center currently manages these arrangements in accordance with its established institutional conflict of interest policy. The remaining authors declare no conflict of interest.